INS and type 1 diabetes mellitus: One of the missions of SWEET is to harmonize care to optimize outcomes of children with T1D worldwide.13,14 In line with this goal, 2 studies in 2009 and 2017 that mapped the accessibility of and reimbursement for insulin and diabetes technologies in Europe6,15 showed that the reimbursement strategy regarding modern technologies is very heterogeneous, even in developed countries.